Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.09T
Market cap1.09T
Price-Earnings ratio
40.73
Price-Earnings ratio40.73
Dividend yield
0.57%
Dividend yield0.57%
Average volume
3.42M
Average volume3.42M
High today
$1,182.73
High today$1,182.73
Low today
$1,145.00
Low today$1,145.00
Open price
$1,155.51
Open price$1,155.51
Volume
2.48M
Volume2.48M
52 Week high
$1,182.73
52 Week high$1,182.73
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 1.09T, Eli Lilly(LLY) trades at $1,161.65. The stock has a price-to-earnings ratio of 40.73 and currently yields dividends of 57.1%.

On 2026-06-08, Eli Lilly(LLY) stock moved within a range of $1,145.00 to $1,182.73. With shares now at $1,161.65, the stock is trading +1.5% above its intraday low and -1.8% below the session's peak.

Trading activity shows a volume of 2.48M, compared to an average daily volume of 3.42M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,182.73 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,182.73 and a low of $623.78.

LLY News

CNBC 44m
Jim Cramer says he can't sell Eli Lilly despite its massive run up. Here's why - CNBC

...

Jim Cramer says he can't sell Eli Lilly despite its massive run up. Here's why - CNBC
Nasdaq 1h
A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.

Key Points Zealand Pharma reported a high drop-out rate in a phase III trial of Survodutide, due to undesirable side effects experienced by patients. That's g...

A Weight-Loss Rival Just Crashed 23%. Why That's Great News for Eli Lilly and Novo Nordisk.
TipRanks 1h
Lilly Advances Early-Stage Asset With Completion of LY4064809 Bioavailability Study

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. This Phase 1 study, officially titled “A Phase 1, Open-label Study of the Abso...

Analyst ratings

85%

of 33 ratings
Buy
84.8%
Hold
9.1%
Sell
6.1%

More LLY News

Investor's Business Daily 3h
Big Pharma Stock Eli Lilly Concocts New Buy Zone

Eli Lilly Leads Medical Stocks To Watch, While Google Finds Support 6/06/2026 Eli Lilly leads three health care stocks to watch as the market appears to be rot...

Big Pharma Stock Eli Lilly Concocts New Buy Zone
TipRanks 3h
Eli Lilly Stock Jumps 4%. The Outlook for Its Weight-Loss Drugs Just Keeps Getting Better

The stock of Eli Lilly (LLY) is up 4% on June 8 following positive trial data for the company’s newest weight-loss drug called Retatrutide. Unlock trusted, dat...

CNBC 3h
Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Key Points Novo Nordisk and Eli Lilly are introducing GLP-1 pills for obesity, and that competition was on display this weekend at the American Diabetes Associa...

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
Benzinga 4h
Eli Lilly Highlights Weight Loss Benefits For Women Across Menopausal Stages

Eli Lilly and Co. (NYSE:LLY) on Sunday presented new analyses showing that women with obesity or overweight achieved significant weight loss with Foundayo acros...

Eli Lilly Highlights Weight Loss Benefits For Women Across Menopausal Stages
TipRanks 4h
‘This Is Compelling’: Citi Pounds the Table on Eli Lilly Stock

Eli Lilly (NYSE:LLY) shares are getting the thumbs up from investors on Monday after new data on its next-generation obesity therapy retatrutide strengthened co...

TipRanks 4h
Evan Seigerman Reiterates Buy on Eli Lilly, Citing Robust Metabolic and Oncology Pipeline and Maintaining $1,300 Price Target

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Eli Lilly & Co, retaining the price target of $1,300.00. Evan Seigerman has given his Buy rati...

Nasdaq 5h
Is Trending Stock Eli Lilly and Company a Buy Now?

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could infl...

Is Trending Stock Eli Lilly and Company a Buy Now?

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.